

SignalSilence® HSP27 siRNA (Human Specific)

✓ 10 µM in 300 µl



Orders ■ 877-616-CELL (2355)
orders@cellsignal.com

Support ■ 877-678-TECH (8324)
info@cellsignal.com

Web ■ www.cellsignal.com

rev. 03/20/07

This product is for *in vitro* research use only and is not intended for use in humans or animals.

	Species	Molecular Wt.	Assays
HSP27 siRNA	H	N/A	50–100 transfections


Introduction: SignalSilence® HSP27 siRNA from Cell Signaling Technology allows the researcher to specifically inhibit HSP27 expression using RNA interference, a method in which gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products are rigorously tested in-house and have been shown to reduce protein expression in specified cell lines.

Directions for use: CST recommends transfection with 100 nM human-specific HSP27 siRNA 48 to 72 hours prior to cell lysis. See Protocol for transfection procedure.

Tested cell lines: HeLa

Background: Heat shock protein (HSP) 27 is one of the small HSPs that are constitutively expressed at different levels in various cell types and tissues. Like other small heat shock proteins, HSP27 is regulated at both the transcriptional and posttranslational levels (1). In response to stress, the expression level of HSP27 increases several-fold to confer cellular resistance to the adverse environmental change. HSP27 is also phosphorylated at serines 15, 78 and 82 by MAPKAP kinase 2 as the result of the activation of the p38 MAP kinase pathway (2,3). Phosphorylation of HSP27 causes a change in its tertiary structure, which shifts from large homotypic multimers to dimers and monomers (4). It has been illustrated that phosphorylation and increased concentration of HSP27 modulates actin polymerization and reorganization (5,6).

Small interfering RNA (siRNA) has been used to specifically silence HSP27 expression in HeLa cells (7).



Western blot analysis of extracts from HeLa cells transfected with 100 nM control siRNA #6201 (-) or HSP27 siRNA (+), using HSP27 (G31) Monoclonal Antibody #2402 and p42 MAP Kinase (3A7) Monoclonal Antibody #9107. The HSP27 (G31) Monoclonal Antibody confirms silencing of HSP27 expression, and p42 MAP Kinase (3A7) Monoclonal Antibody is used to control for loading and specificity of HSP27 siRNA.

Storage: HSP27 siRNA is supplied in RNase-free water. Aliquot and store at -20°C.

SignalSilence® HSP27 siRNA (Human Specific) #6356

Final concentration 100 nM

Companion Products:

SignalSilence® Control siRNA (Fluorescein Conjugate) #6201

SignalSilence® HSP27 siRNA Kit (Human Specific) #6355

HSP27 (G31) Monoclonal Antibody #2402

Phospho-HSP27 (Ser82) Antibody #2401

Phospho-HSP27 (Ser78) Antibody #2405


Phototope-HRP Western Blot Detection System, Anti-mouse IgG, HRP-linked Antibody #7072

Anti-mouse IgG, HRP-linked Antibody #7076

Prestained Protein Marker, Broad Range (Premixed Format) #7720


Biotinylated Protein Ladder Detection Pack #7727

LumiGLO® Reagent and Peroxide #700



**Background References:**

- (1) Arrigo, A.P. and Landry, J. (1994) *Cold Spring Harbor Laboratory Press*, 335–373.
- (2) Landry, J. et al. (1992) *J. Biol. Chem.* 267, 794–803.
- (3) Rouse, J. et al. (1994) *Cell* 78, 1027–1037.
- (4) Rogalla, T. et al. (1999) *J. Biol. Chem.* 274, 18947–18956.
- (5) Lavoie, J. et al. (1993) *J. Biol. Chem.* 268, 24210–24214.
- (6) Rousseau, S. et al. (1997) *Oncogene* 15, 2169–2177.
- (7) Park, K. et al. (2003) *J. Biol. Chem.* 278, 35272–35278



Fluorescent detection of SignalSilence Control siRNA (Fluorescein Conjugate) #6201 in living HeLa cells 24 hours post-transfection, demonstrating nearly 100% transfection efficiency.

License Information

This Product is licensed under European Patents 1144623, 121945 and foreign equivalents from Alnylam Pharmaceuticals, Inc., Cambridge, USA and is provided only for use in academic and commercial research whose purpose is to elucidate gene function, including research to validate potential gene products and pathways for drug discovery and development and to screen non-siRNA based compounds (but excluding the evaluation or characterization of this product as the potential basis for a siRNA-based drug) and not for any other commercial purposes. Information about licenses for commercial use (including discovery and development of siRNA-based drugs) is available from Alnylam Pharmaceuticals, Inc., 300 Third Street, Cambridge, MA 02142, USA.

This Product is sold under license from The Carnegie Institute, U.S. Patent No. 6,506,559 and foreign equivalents. Purchase of Product by academic purchasers includes the pass-through right to use the Product in methods described in Carnegie Patent Rights within the Field of Use. Purchase of Product by corporate or for-profit purchasers does not include the pass-through right to use the Product in any methods described in Carnegie Patent Rights, and a separate license to practice such methods may be required – and sought from – Carnegie.

Species Cross-Reactivity Key: H—human M—mouse R—rat Hm—hamster Mk—monkey Mi—mink C—chicken X—*Xenopus* Z—zebra fish All—all species expected
Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Transfection and Western Immunoblotting Protocol

CST recommends that researchers first confirm that the protein of interest can be detected by Western blotting in lysates from the cell type of interest.

siRNA Transfection Protocol:

Use sterile technique and wear gloves to avoid cell contamination and RNA degradation.

- A.)** Day 1: Trypsinize and plate cells to a 12-well plate in medium containing 10% serum at a density that will allow cells to reach 50% confluence on day 2.
- B.)** Day 2: (Indicated values are for a 12-well plate)
1. Remove medium from cells and replace it with 500 μ l fresh serum-containing medium.
 2. Add 100 μ l of serum-free medium to a clean, sterile microfuge tube.
 3. Add 2 μ l of Transfection Reagent to the tube. Mix by pipetting up and down.
 4. Incubate at room temperature for 5 minutes.
 5. Add the appropriate volume of siRNA (stocks are 10 μ M in RNase-free water) to the tube. For example, add 6 μ l of 10 μ M stock siRNA to the microfuge tube to yield a final concentration of 100 nM, or 3 μ l to yield a concentration of 50 nM, when the mixture is added to the well containing 500 μ l. See data sheet for recommended final siRNA concentration. Mix by pipetting up and down gently.
 6. Incubate for 5 minutes at room temperature.
 7. Add 100 μ l of the mixture to the well containing 500 μ l medium all at once (not drop-wise).
 8. Agitate vigorously to disperse siRNA evenly, but avoid spillage of medium from one well to another.
- C.)** Day 3: Replace the medium with fresh medium. Examine fluorescein-labeled non-specific siRNA-transfected cells using a fluorescence microscope to determine transfection efficiency. For a 24 hour time point, proceed to step "D".
- D.)** Day 4 (48 hour time point): To prepare cell lysates for Western blot analysis, proceed to step 2 of Protein Blotting protocol. CST recommends that researchers perform a preliminary Western blot using control (non-targeted) antibody to detect protein from approximately 7 μ l of each cell lysate to confirm that there is an equal concentration of cellular protein in each sample.

Solutions and Reagents

Note: Prepare solutions with Milli-Q or equivalently purified water.

Transfer Buffer:

25 mM Tris base, 0.2 M glycine, 20% methanol (pH 8.5)

SDS Sample Buffer (1X):

62.5 mM Tris-HCl (pH 6.8 at 25°C), 2% w/v SDS, 10% glycerol, 50 mM DTT, 0.01% w/v bromophenol blue or phenol red

Blocking Buffer:

1X TBS, 0.1% Tween-20 with 5% w/v nonfat dry milk; for 150 ml, add 15 ml 10X TBS to 135 ml water, mix. Add 7.5 g nonfat dry milk and mix well. While stirring, add 0.15 ml Tween-20 (100%).

10X TBS (Tris-buffered saline):

To prepare 1 liter of 10X TBS: 24.2 g Tris base, 80 g NaCl; adjust pH to 7.6 with HCl (use at 1X).

Primary Antibody Dilution Buffer:

1X TBS, 0.1% Tween-20 with 5% BSA (for polyclonal antibodies) or 5% nonfat dry milk (for monoclonal antibodies or a combination of a polyclonal and a monoclonal antibody); for 20 ml, add 2 ml 10X TBS to 18 ml water, mix. Add 1.0 g BSA or nonfat dry milk and mix well. While stirring, add 20 μ l Tween-20 (100%).

Phototope®-HRP Western Blot Detection:

Biotinylated protein marker, secondary antibody conjugated to horseradish peroxidase (HRP), anti-biotin antibody conjugated to HRP, LumiGLO™ chemiluminescent reagent, peroxide

Wash Buffer TBS/T:

1X TBS, 0.1% Tween-20

Blotting Membrane

This protocol has been optimized for nitrocellulose membranes, which we recommend. PVDF membranes may also be used.

Protein Blotting

A general protocol for sample preparation is described below.

1. Treat cells by adding fresh media containing regulator for desired time.
2. Aspirate media from cultures; wash cells twice with 1X PBS; aspirate.
3. Lyse cells by adding 1X SDS Sample Buffer (50 μ l per well of 12-well plate). Immediately scrape the cells off the plate and transfer the extract to a microcentrifuge tube. Keep on ice.
4. Sonicate for 10–15 seconds to shear DNA and reduce sample viscosity.
5. Heat a 20 μ l sample to 95–100°C for 5 minutes; cool on ice.
6. Microcentrifuge for 5 minutes.
7. Load 20 μ l onto SDS-PAGE gel (10 cm x 10 cm).

Note: CST recommends loading prestained molecular weight markers (#7720, 10 μ l/lane) to verify electrotransfer and biotinylated protein markers (#7727, 10 μ l/lane) to determine molecular weights.

8. Electrotransfer to nitrocellulose membrane.

For Western blots, incubate membrane with diluted antibody in 5% BSA, (for polyclonal antibodies) or 5% nonfat dry milk (for monoclonal antibodies or a combination of a polyclonal and a monoclonal antibody). 1X TBS, 0.1% Tween-20 at 4°C with gentle shaking, overnight.

Western Immunoblotting Protocol

Membrane Blocking and Antibody Incubations

Note: Volumes are for 10 cm x 10 cm (100 cm²) of membrane; for different sized membranes, adjust volumes accordingly.

1. (Optional) After transfer, wash nitrocellulose membrane with 25 ml TBS for 5 minutes at room temperature.
2. Incubate membrane in 25 ml of Blocking Buffer for 1 hour at room temperature.
3. Wash 3 times for 5 minutes each with 15 ml of TBS/T.
4. Incubate membrane and primary antibody with loading control antibody (at the appropriate dilution) in 10 ml Primary Antibody Dilution Buffer with gentle agitation overnight at 4°C.
5. Wash 3 times for 5 minutes each with 15 ml of TBS/T.
6. Incubate membrane with HRP-conjugated secondary antibody (dilution varies with manufacturer) and HRP-conjugated anti-biotin antibody (1:1000) to detect biotinylated protein markers (if using) in 10 ml of Blocking Buffer with gentle agitation for 1 hour at room temperature.
7. Wash 3 times for 5 minutes each with 15 ml of TBS/T.

Detection of Proteins

1. Incubate membrane with 10 ml LumiGLO™ (0.5 ml 20X LumiGLO™, 0.5 ml 20X Peroxide and 9.0 ml Milli-Q water) with gentle agitation for 1 minute at room temperature.

Note: LumiGLO™ Substrate can be further diluted if signal response is too fast.

2. Drain membrane of excess developing solution, do not let dry, wrap in plastic wrap and expose to x-ray film. An initial ten-second exposure should indicate the proper exposure time.

Note: Due to the kinetics of the detection reaction, signal is most intense immediately following LumiGLO™ incubation and declines over the following 2 hours.